Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Enloe Medical Center — Chico, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Epic Care-Dublin — Dublin, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Mattel Children's Hospital UCLA — Los Angeles, California
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Valley Children's Hospital — Madera, California
- Kaiser Permanente-Oakland — Oakland, California
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in California: - University of Southern California — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Stanford Cancer Institute — Palo Alto, California
- University of California — San Francisco, California
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- University of California, San Diego / Rady Children's Hospital, San Diego — San Diego, California
- University of California, San Francisco — San Francisco, California
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in California: - City of Hope--Duarte — Duarte, California
- Cancer & Blood Research Center, LLC — Los Alamitos, California
- Univ. of California Los Angeles — Los Angeles, California
- FOMAT Medical Research (Network) — Oxnard, California
- Scripps Health — San Diego, California
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in California: - UCSF Benioff Children's Hospital — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed …
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT02704858
Sites in California: - University of Southern California — Los Angeles, California
- Saint John Cancer Institute — Santa Monica, California
Phase 2 Recruiting Network
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual app…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06319027
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in California: - Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Francisco, California
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in California: - Lucille Packard Children's Hospital Stanford — Palo Alto, California
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in California: - Cedars Sinai Medical Center — Los Angeles, California
Phase 2 Recruiting Academic/Other
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated…
Sponsor: Scott R. Plotkin, MD, PhD
NCT ID: NCT04374305
Sites in California: - UCLA Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Academic/Other
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate …
Sponsor: University of California, San Francisco
NCT ID: NCT06504381
Sites in California: - University of Southern California — Los Angeles, California
- University of California, San Diego — San Diego, California
- University of California — San Francisco, California
Phase 2 Recruiting Academic/Other
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard …
Sponsor: Cedars-Sinai Medical Center
NCT ID: NCT05708352
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- Pacific Neuroscience Institute / Saint John's Cancer Institute — Santa Monica, California
Phase 2 Recruiting Industry
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The …
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06061809
Sites in California: - Chan Soon-Shiong Institute for Medicine (CSSIFM) — El Segundo, California
- Providence Medical Foundation — Fullerton, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
Phase 2 Recruiting Academic/Other
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Sponsor: Duke University
NCT ID: NCT06069726
Sites in California: - University of California, San Francisco — San Francisco, California
Phase 1, Phase 2 Recruiting Academic/Other
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portio…
Sponsor: Joshua Palmer
NCT ID: NCT05987644
Sites in California: - Stanford University — Stanford, California
Phase 1, Phase 2 Recruiting Academic/Other
The objective of the study is to assess safety of panitumumab-IRDye800 in pediatric patients undergoing brain surgery to remove suspected tumors.
Sponsor: Stanford University
NCT ID: NCT04085887
Sites in California: - Stanford Cancer Center — Stanford, California
Phase 2 Recruiting Academic/Other
In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and …
Sponsor: Jona Hattangadi-Gluth
NCT ID: NCT04343157
Sites in California: - Moores Cancer Center — San Diego, California